rDEN4σ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

Journal of Infectious Diseases

Volumn 191, Issue 5, 2005, Pages 710-718

  Durbin, Anna P ^a   Whitehead, Stephen S ^b   McArthur, Julie ^a   Perreault, John R ^a   Blaney Jr , Joseph E ^b   Thumar, Bhavin ^a   Murphy, Brian R ^b   Karron, Ruth A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE VIRUS; DENGUE VIRUS 4; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERANCE; ERYTHEMA; EYE PAIN; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN INDURATION; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; GENETICS; IMMUNOLOGY; MIDDLE AGED; VIREMIA;

ADULT; ANTIBODIES, VIRAL; DENGUE VIRUS; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIREMIA;

EID: 13944278364     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427780     Document Type: Article

References (46)

1. Lindenback B, Rice C. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Vol. 1. Baltimore: Lippincott Williams & Wilkins, 2001:963-1041.
2. Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Vol. 1. Baltimore: Lippincott Williams and Wilkins, 2001:1043-125.
3. World Health Organization. Dengue prevention and control: report by the Secretariat. Fifty-Fifth World Health Assembly (provisional agenda item 13.14, document no. A55/19). Geneva: WHO, 2002.
4. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: WHO, 1997.
5. Sabin A. Recent advances in our knowledge of dengue and sandfly fever. Am J Trop Med Hyg 1955; 4:198-207.
6. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172-80.
7. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001; 65:405-13.
8. Troyer JM, Hanley KA, Whitehead SS, et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg 2001; 65:414-9.
9. Clarke DH, Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 1958; 7:561-73.
10. Wisseman CJ, Sweet B, Rosenzweig E, Eylar O. Attenuated living type 1 dengue vaccines. Am J Trop Med Hyg 1963; 12:620-3.
11. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 1987; 65:189-95.
12. Hoke CH Jr, Malinoski FJ, Eckels KH, et al. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 1990; 43:219-26.
13. Bancroft WH, Scott RM, Eckels KH, et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 1984; 149:1005-10.
14. McKee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987; 36:435-42.
15. Kanesa-Thasan N, Edelman R, Tacket CO, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003; 69:17-23.
16. Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:24-31.
17. Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
18. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18:44-7.
19. Kanesa-Thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179-88.
20. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70:3930-7.
21. Anderson R, King AD, Innis BL. Correlation of E protein binding with cell susceptibility to dengue 4 virus infection. J Gen Virol 1992; 73:2155-9.
22. Gubler D, Kuno G. Dengue and dengue hemorrhagic fever. New York: CAB International, 1997.
23. Huang CY, Butrapet S, Pierro DJ, et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000; 74:3020-8.
24. Kinney RM, Butrapet S, Chang GJ, et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997; 230:300-8.
25. Wang E, Ni H, Xu R, et al. Evolutionary relationships of endemic/ epidemic and sylvatic dengue viruses. J Virol 2000; 74:3227-34.
26. Henchal EA, Repik PM, McCown JM, Brandt WE. Identification of an antigenic and genetic variant of dengue-4 virus from the Caribbean. Am J Trop Med Hyg 1986; 35:393-400.
27. Lanciotti RS, Gubler DJ, Trent DW Molecular evolution and phylogeny of dengue-4 viruses. J Gen Virol 1997; 78:2279-84.
28. Guirakhoo F, Zhang Z, Myers G, et al. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol 2004; 78:9998-10008.
29. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-18.
30. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188:1213-30.
31. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 1945; 101:640-2.
32. Sabin A. Dengue. In: Rivers T, Horsfall F, eds. Viral and rickettsial infections of man. 3rd ed. Philadelphia: JB Lippincott Company, 1959:361-73.
33. Halstead SB, O'Rourke EJ, Allison AC. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med 1977; 146:218-29.
34. Scott RM, Nisalak A, Cheamudon U, Seridhoranakul S, Nimmannitya S. Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever. J Infect Dis 1980; 141:1-6.
35. Wu SJ, Grouard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6:816-20.
36. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. Human dendritic cells are activated by dengue virus infection: enhancement by gamma Interferon and implications for disease pathogenesis. J Virol 2001; 75:3501-8.
37. Hober D, Poli L, Roblin B, et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 1993; 48:324-31.
38. Shaio MF, Cheng SN, Yuh YS, Yang KD. Cytotoxic factors released by dengue virus-infected human blood monocytes. J Med Virol 1995; 46:216-23.
39. Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 1997; 71:4226-32.
40. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23:99-109.
41. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66:264-72.
42. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
43. Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003; 77:1653-7.
44. Whitehead SS, Hanley KA, Blaney JE Jr, Gilmore LE, Elkins WR, Murphy BR. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003; 21:4307-16.
45. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004; 71:811-21.
46. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 2003; 314:190-5.